In the next issue, we kick off the new year with our predictions for the pharmaceutical and biotech sectors in 2023. The year will be marked with the entry of biosimilars to AbbVie’s blockbuster Humira and we take a look at the several competitors vying to gain the most profits as the anti-TNF drug gets edged off its position as the top-selling biologic in recent years.
With the help of data, we will also take a look at trends in mergers and acquisitions over 2022, and what can be expected with deals in this space amidst the ongoing energy and financial crises.
Editor | Manasi Vaidya
Writers | Urtė Fultinavičiūtė, Irena Maragkou, Akosua Mireku, William Newton, Adam Zamecnik
Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Noemi Balint, Martina Labaiova, Tyrrell Lowe, Ashley McPherson
Lead Designer | John Hammond
Publisher | Susanne Hauner
Sales Manager | Tom McCormick
+44 207 8669440
Cover image: Composite. Credit: PremiumArt, Ardea-studio and Will Ingham
Pharma Technology Focus is powered by H5mag
Read past issues of Pharma Technology Focus HERE
Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.